Are GLP-1 drugs the new trend in weight loss, or a threat to the body positivity movement? A recent survey reveals that GLP-1 drugs, such as Ozempic and Mounjaro, are becoming increasingly popular among Canadians, with around three million adults currently taking them. The survey also found that many more are interested in trying them, but cost is a significant barrier. The drugs have been shown to reduce appetite and cravings, leading to changes in spending habits. About 30% of users reported eating out or ordering takeout less often, while 36% said they decreased their alcohol consumption. Additionally, 35% of users said they order smaller portions or choose healthier options. However, the rise of GLP-1 drugs has sparked controversy and raised questions about the body positivity movement. Some argue that the drugs are a promising solution for weight loss, while others worry that they may undermine the movement's message of self-acceptance and body positivity. The survey also found that cost is a significant barrier to access, with only 28% of users having full insurance coverage for the drugs. This highlights the need for more affordable options and better insurance coverage for these medications. So, what's the verdict? Are GLP-1 drugs the new trend in weight loss, or a threat to the body positivity movement? The answer may lie in finding a balance between the benefits of the drugs and the importance of promoting body positivity and self-acceptance. As the debate continues, it's clear that more research and discussion are needed to fully understand the impact of GLP-1 drugs on our society and our health.
